Dr. Dixon on Letrozole With Pathway Inhibitors

J. Michael Dixon, MD
Published: Thursday, Sep 15, 2011

J. Michael Dixon, MBChB, MD, Professor of Surgery and Consultant Surgeon of the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland, explains the potential to combine letrozole with targeted therapies.

Dixon cites a neoadjuvant trial that examined the mTOR inhibitor RAD001 (everolimus) plus letrozole. This trial showed benefit, but with too much toxicity. This trial showed it was possible to combine letrozole with targeted agents. This will lead to further investigation in the future.
 
J. Michael Dixon, MBChB, MD, Professor of Surgery and Consultant Surgeon of the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland, explains the potential to combine letrozole with targeted therapies.

Dixon cites a neoadjuvant trial that examined the mTOR inhibitor RAD001 (everolimus) plus letrozole. This trial showed benefit, but with too much toxicity. This trial showed it was possible to combine letrozole with targeted agents. This will lead to further investigation in the future.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x